Index by author

July 01, 2011; Volume 78,Issue 7

C

  1. Castro, Mario

    1. Bronchial thermoplasty: A new treatment for severe refractory asthma
      Bronchial thermoplasty: A new treatment for severe refractory asthma
      Thomas R. Gildea, MD, MS, Sumita B. Khatri, MD, MS and Mario Castro, MD, MPH
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 477-485; DOI: https://doi.org/10.3949/ccjm.78a.10185

      Asthma has a new treatment, but it isn’t for everybody. Here, we review its indications, evidence of efficacy, and protocols.

G

  1. Gildea, Thomas R.

    1. Bronchial thermoplasty: A new treatment for severe refractory asthma
      Bronchial thermoplasty: A new treatment for severe refractory asthma
      Thomas R. Gildea, MD, MS, Sumita B. Khatri, MD, MS and Mario Castro, MD, MPH
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 477-485; DOI: https://doi.org/10.3949/ccjm.78a.10185

      Asthma has a new treatment, but it isn’t for everybody. Here, we review its indications, evidence of efficacy, and protocols.

H

  1. Hogarth, D. Kyle

    1. Bronchial thermoplasty: A promising therapy, still in its infancy
      Amit K. Mahajan, MD and D. Kyle Hogarth, MD, FCCP
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 475-476; DOI: https://doi.org/10.3949/ccjm.78a.11063

      Inflammation is not the only pathophysiologic process underlying asthma. Bronchial thermoplasty takes a novel approach and offers reason for optimism.

I

  1. Induru, Raghava R.

    1. Managing cancer pain: Frequently asked questions
      Raghava R. Induru, MD and Ruth L. Lagman, MD, MPH, FACP
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 449-464; DOI: https://doi.org/10.3949/ccjm.78a.10054

      Cancer pain: its pathogenesis, how to assess it, and how to treat it—in particular, how to use opioids optimally.

J

  1. Jaffer, Amir K.

    1. Update in hospital medicine: Studies likely to affect inpatient practice in 2011
      Amir K. Jaffer, MD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 430-434; DOI: https://doi.org/10.3949/ccjm.78gr.11002

      A hypothetical case scenario helps focus on anticoagulants, patient safety, quality improvement, critical care, transitions of care, and perioperative medicine.

K

  1. Khatri, Sumita B.

    1. Bronchial thermoplasty: A new treatment for severe refractory asthma
      Bronchial thermoplasty: A new treatment for severe refractory asthma
      Thomas R. Gildea, MD, MS, Sumita B. Khatri, MD, MS and Mario Castro, MD, MPH
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 477-485; DOI: https://doi.org/10.3949/ccjm.78a.10185

      Asthma has a new treatment, but it isn’t for everybody. Here, we review its indications, evidence of efficacy, and protocols.

L

  1. Lagman, Ruth L.

    1. Managing cancer pain: Frequently asked questions
      Raghava R. Induru, MD and Ruth L. Lagman, MD, MPH, FACP
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 449-464; DOI: https://doi.org/10.3949/ccjm.78a.10054

      Cancer pain: its pathogenesis, how to assess it, and how to treat it—in particular, how to use opioids optimally.

M

  1. Mahajan, Amit K.

    1. Bronchial thermoplasty: A promising therapy, still in its infancy
      Amit K. Mahajan, MD and D. Kyle Hogarth, MD, FCCP
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 475-476; DOI: https://doi.org/10.3949/ccjm.78a.11063

      Inflammation is not the only pathophysiologic process underlying asthma. Bronchial thermoplasty takes a novel approach and offers reason for optimism.

  2. Mandell, Brian F.

    1. When good drugs turn weirdly bad
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 426; DOI: https://doi.org/10.3949/ccjm.78b.11007

      Even the most specific of drugs, such as interferon, can have untoward biologic effects.

  3. Menon, Venu

    1. Hypothermia after cardiac arrest: Beneficial, but slow to be adopted
      Santosh Samuel Oommen, MD and Venu Menon, MD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 441-448; DOI: https://doi.org/10.3949/ccjm.78a.10157

      Survivors of cardiac arrest due to ventricular tachycardia or ventricular fi brillation have better neurologic outcomes if they are cooled to a core body temperature of 32°C to 34°C for 24 hours as soon as possible after reaching the hospital.

N

  1. Neuner, Elizabeth

    1. Vancomycin: A 50-something-yearold antibiotic we still don’t understand
      Amy Schilling, PharmD, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 465-471; DOI: https://doi.org/10.3949/ccjm.78a.10168

      To use vancomycin appropriately, we need to recognize its changing minimum inhibitory concentrations, select proper doses and dosing intervals, and know how to monitor its use.

O

  1. Oommen, Santosh Samuel

    1. Hypothermia after cardiac arrest: Beneficial, but slow to be adopted
      Santosh Samuel Oommen, MD and Venu Menon, MD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 441-448; DOI: https://doi.org/10.3949/ccjm.78a.10157

      Survivors of cardiac arrest due to ventricular tachycardia or ventricular fi brillation have better neurologic outcomes if they are cooled to a core body temperature of 32°C to 34°C for 24 hours as soon as possible after reaching the hospital.

R

  1. Rehm, Susan J.

    1. Vancomycin: A 50-something-yearold antibiotic we still don’t understand
      Amy Schilling, PharmD, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 465-471; DOI: https://doi.org/10.3949/ccjm.78a.10168

      To use vancomycin appropriately, we need to recognize its changing minimum inhibitory concentrations, select proper doses and dosing intervals, and know how to monitor its use.

S

  1. Schilling, Amy

    1. Vancomycin: A 50-something-yearold antibiotic we still don’t understand
      Amy Schilling, PharmD, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 465-471; DOI: https://doi.org/10.3949/ccjm.78a.10168

      To use vancomycin appropriately, we need to recognize its changing minimum inhibitory concentrations, select proper doses and dosing intervals, and know how to monitor its use.

T

  1. Tang, Derek M.

    1. Rash from hepatitis C treatment
      Derek M. Tang, MD and Lawrence Ward, MD, MPH
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 472-474; DOI: https://doi.org/10.3949/ccjm.78a.10124

      Although the combination of interferon and ribavirin is the standard of treatment for chronic hepatitis C, some patients experience adverse reactions.

W

  1. Ward, Lawrence

    1. Rash from hepatitis C treatment
      Derek M. Tang, MD and Lawrence Ward, MD, MPH
      Cleveland Clinic Journal of Medicine July 2011, 78 (7) 472-474; DOI: https://doi.org/10.3949/ccjm.78a.10124

      Although the combination of interferon and ribavirin is the standard of treatment for chronic hepatitis C, some patients experience adverse reactions.

Back to top

In this issue